Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Broncus Holding HK$1.55 billion IPO
We advised Broncus on its IPO and HKEX listing
Eli Lilly €1.8 billion and £250 million notes offering
The investment-grade offering included the company’s inaugural sustainability bonds
Maravai LifeSciences $1 billion secondary offering
The shares are listed on the Nasdaq Global Select Market
PerkinElmer $2.3 billion senior notes offering
We advised the underwriters on the investment-grade debt offering
MultiPlan $1.05 billion notes offering and $1.775 billion credit facility
We advised the initial purchasers on the secured high-yield debt offering and the lead arrangers on the new credit agreement
Triple-S Management $900 million acquisition by GuideWell
We are advising Triple-S on the transaction
Kora Saúde R$770 million IPO
We advised the joint bookrunners on the IPO and São Paulo Stock Exchange listing
Magnolia Medical Technologies patent litigation against Kurin
We are serving as lead trial counsel for Magnolia Medical in an action against its sole competitor
Signify Health trade-secret case against CareCentrix
We are defending Signify Health against trade-secret-misappropriation and related claims
Adagio Therapeutics $356 million IPO
We advised the underwriters on the IPO and Nasdaq listing